Guggenheim Initiates Coverage on Enliven Therapeutics (NASDAQ:ELVN)

Guggenheim initiated coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research note issued on Tuesday. The firm set a “buy” rating and a $80.00 price target on the stock. Guggenheim’s price objective points to a potential upside of 102.07% from the company’s current price.

ELVN has been the topic of a number of other research reports. The Goldman Sachs Group boosted their price target on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Mizuho boosted their price target on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 25th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Finally, HC Wainwright boosted their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.17.

Enliven Therapeutics Stock Performance

ELVN opened at $39.59 on Tuesday. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $48.53. The firm has a market capitalization of $2.41 billion, a PE ratio of -23.71 and a beta of 0.32. The business’s 50-day simple moving average is $37.48 and its 200 day simple moving average is $27.59.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. On average, research analysts forecast that Enliven Therapeutics will post -1.7 earnings per share for the current year.

Insider Activity at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 1,230 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total value of $32,201.40. Following the transaction, the director owned 22,647 shares of the company’s stock, valued at approximately $592,898.46. This represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Benjamin Hohl sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at $1,508,580. The trade was a 16.39% decrease in their position. The SEC filing for this sale provides additional information. 25.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. Invesco Ltd. grew its position in shares of Enliven Therapeutics by 4.3% in the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after purchasing an additional 913 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. KBC Group NV acquired a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $38,000. Finally, Swiss National Bank grew its position in shares of Enliven Therapeutics by 1.7% in the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock valued at $990,000 after purchasing an additional 1,100 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.